Articles - Dyadic International, Inc :Dyadic International, Inc

Home
C1 Uses
C1 Technology
Investors
Media Center
About
Careers
Contact Us

Vaccines
Antibodies
BIOSIMILARS
BIOBETTERS
BIOPHARMACEUTICALS
ENZYME THERAPIES
ANIMAL HEALTH
BIOTHERAPEUTIC MANUFACTURING
ENZYME CATALYSTS

C1 Expression System
Licensees / Collaborators
Manufacturing
R&D Facilities
The White Strain™

Analysts
Corporate Profile
Corporate Governance
Filings and Disclosures
Financial Statements
Proxy Statements
Stock Information

The Dyadic Story
Executives & Advisors
Careers
Contact Us

Events
Press Releases
Articles
Presentations
Scientific Publications
Video Gallery

Articles

All 2022 2021 2020 2019 2018 2017 2015 2014 2013 2012 2011 2010 2009 2007 2006

Health Awareness June 21, 2022
Protected: Creating a more affordable and efficient vaccine development platform

Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.

Sitemap

Home
C1 Uses
C1 Technology
Investors
Media Center
About
Contact Us

© Dyadic International Inc., 2022. Website by Daniels + Roberts, Inc